These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9586599)

  • 1. Army and Air Force leadership in the Prostate Cancer Prevention Trial.
    Allerton J; Seay T; Optenberg S; Coltman CA; Higgins B; Thompson I; Lovato L
    Urology; 1998 Apr; 51(4A Suppl):64-6. PubMed ID: 9586599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial.
    Thompson IM; Coltman CA; Crowley J
    Prostate; 1997 Nov; 33(3):217-21. PubMed ID: 9365551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on chemoprevention of prostate cancer.
    Klein EA; Thompson IM
    Curr Opin Urol; 2004 May; 14(3):143-9. PubMed ID: 15069304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
    Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
    Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pathologist's perspective on the PCPT trial].
    Molinié V; Allory Y
    Prog Urol; 2008 Apr; 18 Suppl 3():S47-52. PubMed ID: 18455084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prostate Cancer Prevention Trial: Current status and lessons learned.
    Thompson IM; Kouril M; Klein EA; Coltman CA; Ryan A; Goodman P
    Urology; 2001 Apr; 57(4 Suppl 1):230-4. PubMed ID: 11295634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Cancer Prevention Trial (PCPT) update.
    Coltman CA; Thompson IM; Feigl P
    Eur Urol; 1999; 35(5-6):544-7. PubMed ID: 10325520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of finasteride on risk of prostate cancer: how little we really know.
    Rubin MA; Kantoff PW
    J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prostate Cancer Prevention Trial: current status.
    Higgins B; Thompson IM
    J Urol; 2004 Feb; 171(2 Pt 2):S15-7; discussion S8. PubMed ID: 14713747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical implications of the prostate cancer prevention trial.
    Marberger M; Adolfsson J; Borkowski A; Fitzpatrick J; Kirk D; Prezioso D; Rabaça C; Solsona E; Teillac P
    BJU Int; 2003 Nov; 92(7):667-71. PubMed ID: 14616442
    [No Abstract]   [Full Text] [Related]  

  • 18. New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer.
    Ankerst DP; Thompson IM
    Arch Ital Urol Androl; 2006 Dec; 78(4):154-6. PubMed ID: 17269622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-alpha-reductase Inhibitors for prostate cancer prevention.
    Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD007091. PubMed ID: 18425978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
    Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
    Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.